Publications
5674 Results
- Journal / Conference
- Blood 118:abstract 661 (oral presentation)
- Year
- 2011
- Research Committee(s)
- Lymphoma
Randomized phase III trial of 131 iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS)
- Journal / Conference
- Haematologica 96(s1):S78, poster #167 (International Myeloma Workshop)
- Year
- 2011
- Research Committee(s)
- Myeloma
- Study Number(s)
- S0232
Extended results of Southwest Oncology Group protocol S0232: durable responses achieved with lenalidomide (L) plus high-dose dexamethason (D) as first-line therapy for multiple myeloma
- Journal / Conference
- Health Affairs 30(12):2259-2268
- Year
- 2011
- Research Committee(s)
- Breast
- PMID
- PMID22147853
- PMC
- PMC3477796
- Study Number(s)
- S1007
How comparativeness effectiveness research can help advance "personalized medicine" in cancer treatment
- Journal / Conference
- Breast Cancer Research and Treatment 126(1):215-220
- Year
- 2011
- Research Committee(s)
- Breast
- PMID
- PMID20976543
- PMC
- pending
Evaluation of metformin in early breast cancer: a modification of the traditional pardigm for clinical testing of anti-cancer agents
- Journal / Conference
- Journal of Clinical Oncology 29:(suppl; abstr TPS103), ASCO annual meeting, Trials in Progress, poster presentation;
- Year
- 2011
- Research Committee(s)
- Breast
A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32)
- Journal / Conference
- Journal of Clinical Oncology 29(25):3366-3373
- Year
- 2011
- Research Committee(s)
- Breast
- PMID
- PMID21768458
- PMC
- PMC3164242
- Study Number(s)
- N9831
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.
- Journal / Conference
- Journal of Clinical Oncology Vol 29, No 15_suppl (May 20 Supplement), 2011: abst. 8505; ASCO Annual Meeting ((June 4-8, 2011, Chicago, IL), oral;
- Year
- 2011
- Research Committee(s)
- Melanoma
- Study Number(s)
- CTSU/E1697
Randomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate and high-risk melanoma (Intergroup trial E 1697)
- Journal / Conference
- American Journal of Clinical Oncology, Apr; 33(2):117-120;
- Year
- 2010
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID19770625
- PMC
- PMC2967385
- Study Number(s)
- SWOG-9511
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach
- Journal / Conference
- Head and Neck, Feb; 32(2):221-228;
- Year
- 2010
- Research Committee(s)
- Head and Neck
- Study Number(s)
- S0216
Docetaxel, cisplatin and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) [PMID: 19557750;PMC2967367]
- Journal / Conference
- Lancet Oncology 11:55-65
- Year
- 2010
- Research Committee(s)
- Breast
- Study Number(s)
- SWOG-8814